Linking Pharmacy Professionals to the World Wide Web Home | WebMail | Site Map | About Us | Help   Pharmacy and Pharmacist Jobs, Education and Resources
Pharmacy and Pharmacist Jobs, Education, News and Resources

 News | Careers | Resources | Education | Business | Marketplace
Search:
 Saturday, July 4 New User? Register Here     Log In  

Resources » Food and Drug Administration (FDA) » News and Announcements

News and Announcements Consumer Publications
Pregnancy Exposure Registries Medication Guides    

 Today's FDA Final Approvals
News Articles Custom Tag
Read All news articles about FDA Final Approvals

FDA For more information on the FDA, please visit FDA.gov

The latest announcements from the Center for Drug Evaluation and Research:

  • May 20 - FDA updates information for Tamiflu: Dosing recommendations for infants and technical documents. H1N1 Flu.


  • May 5 - FDA issues an Update about Suicidal Behavior and Ideation and Antiepileptic Drugs. Drug Information.


  • May 4 - FDA updates information on the 2009 H1N1 Flu Virus. H1N1 Flu.


  • May 1 - FDA approves pancrelipase (Creon Delayed-Release Capsules) for adult and pediatric patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis, and other conditions. Drug Information.


  • April 30 - FDA updates the Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). Information.


  • April 29 - FDA updates information on the 2009 H1N1 Flu Virus. Information.


  • April 22 - FDA updates action on Plan B (levonorgestrel) tablets. FDA Statement.


  • April 14 - FDA imposes restrictions on Coast IRB due to violations. FDA News.


  • April 14 - FDA issues Information for Healthcare Professionals: Ceftriaxone (marketed at Rocephin and generics). Information.


  • April 9 - FDA adopts an interim plan to avoid shortage of a medically necessary opioid. FDA News.


  • April 8 - Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announces that it has begun a voluntary, phased withdrawal of the product from the U.S. market. FDA Statement.


  • March 31 - FDA acts to halt marketing of certain unapproved prescription narcotic drugs. FDA News.


  • March 19 - FDA issues Information for Healthcare Professionals: Risk of Transmission of Blood-borne Pathogens from Shared Use of Insulin Pens. Information.


  • March 10 - FDA issues position on allowing patients with ALS access to Iplex under an IND. Information.


  • March 5 - Public Health Advisory: Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings. Information.


  • February 25 - FDA takes new regulatory action against Ranbaxy’s Paonta Sahib plant in India. FDA News.


  • February 23 - Information for Healthcare Professionals for Zonisamide. Information.


  • February 19 - FDA issues Updated Safety Information about Raptiva (efalizumab). Information.


  • February 9 - FDA to meet with drug companies about REMS for certain opioid drugs. Information.


  • February 4 - FFDA issues an Early Communication about an Ongoing Safety Review Xigris (Drotrecogin alfa [activated]) Drug Information.


  • January 16 - FDA Public Health Advisory Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions. Drug Information.


  • January 26 - FDA issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) Drug Information.


  • January 16 - Follow-up to FDA Public Health Advisory Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditionso the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) Information.


  • January 13 - Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair). Information.


  • January 8 - Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor). Information.


Files with are .pdf files. You must have Adobe Acrobat to view these files. Click here for free download from Adobe.


Search A Catalog of FDA Approved Drug Products from Drugs@FDA

Search Additions/Deletions for Prescription and OTC Drug Product Lists from FDA.gov

 Free Membership
Click Here to register to Win an iPod nano.
Rules and Regulations
Enjoy Free CE, Drug Search, industry newsletters and more...

 FDA News
Click Here for the latest FDA news from Pharmacy Choice

 Quick Links
Quick Links From FDA.gov
  • Drug Information Pathfinder
  • Drug Shortages
  • Drugs@FDA
  • Inactive Ingredient
  • Database
  • MedWatch
  • National Drug Code Directory
  • Orange Book
  • Postmarketing
  • Study Commitments

    Additional Links From FDA.gov
  • Advisory Committees
  • Bioterrorism
  • CDERLearn (Online Courses)
  • Drug Application Process
  • FDA Patient Safety News with Videos
  • Guidances
  • Hurricane Recovery
  • Jobs at CDER
  • Oncology Tools
  • Pediatrics
  • Pharmaceutical cGMPs: A Risk-Based Approach
  • Small Business
  • Therapeutic Biological Products


  • PatientAssistance







    Most Popular Links: Pharmacy Jobs | Pharmacy CE | Pharmacy News| Drug Data   Pharmacy Choice Advertising Info

    News | Resources | Computing | Marketplace | Careers | Education | Govt./Legal | PharmacyTech | Business

    Home | Advertise | Company Info | Contact Us | Free Registration | Check Email

    RxCareerCenter.com | RxSchool.com | RxProHealth.com | RxTechSchool.com | PharmacyPages.com | RxImmigration.com | RxPost.net | NursingJobSource.com | NurseZone.com | RN.com

    Copyright © 2009 Pharmacy Choice - All rights reserved.  Terms of Service

     Privacy Statement

    888-682-4415